Screening and Management of Chronic Kidney Disease in Individuals Potentially Exposed to Agent Orange

Screening Criteria (KDIGO)

Use the KDIGO definition of CKD: urine albumin‑to‑creatinine ratio (UACR) ≥ 30 mg/g persisting for ≥ 3 months as a threshold for albuminuria screening. 1
Use the KDIGO definition of CKD: estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² persisting for ≥ 3 months as a threshold for reduced kidney function screening. 2

In patients with diabetes, consider alternative (non‑diabetic) causes of CKD when any of the following are present:
Referral to nephrology is recommended when the above atypical features are identified, to ensure appropriate diagnostic work‑up. 4

Manage CKD according to established evidence‑based protocols irrespective of Agent Orange exposure history. This includes lifestyle, dietary, and pharmacologic measures endorsed by KDIGO and the American Journal of Kidney Diseases. [1][2]5
Optimize blood pressure to slow CKD progression, following contemporary hypertension guidelines. [4][3]
Initiate an ACE inhibitor or ARB when UACR ≥ 30 mg/g (or equivalent albuminuria) is documented, with appropriate monitoring for renal function and electrolytes. [4][3]
For patients with both diabetes and CKD, add an SGLT2 inhibitor to reduce progression and cardiovascular risk, per Diabetes Care recommendations. [4][3]
Refer to nephrology when eGFR < 30 mL/min/1.73 m² or when there is evidence of rapidly progressive disease. [4][3]
While on ACE inhibitors, ARBs, or diuretics, regularly monitor serum creatinine and potassium to detect adverse effects early. [4][3]

Do not attribute CKD solely to Agent Orange exposure without first evaluating traditional risk factors such as diabetes, hypertension, and aging. The epidemiologic data do not support a direct causal link.
Do not discontinue renin‑angiotensin system blockade for minor creatinine rises (≤ 30 %) unless there is clear evidence of volume depletion or other contraindication. 4

Chronic kidney disease is defined by an estimated glomerular filtration rate ≤ 60 mL/min/1.73 m² or a physician’s diagnosis of CKD, consistent with KDIGO (Kidney Disease: Improving Global Outcomes) criteria. 6

For any person with a history of possible Agent‑Orange exposure, screen for CKD using the standard KDIGO criteria: urine albumin‑to‑creatinine ratio (UACR) ≥ 30 mg/g creatinine and/or eGFR < 60 mL/min/1.73 m² persisting for ≥ 3 months. This recommendation is supported by the Annals of Internal Medicine guidelines and reinforced by Diabetes Care evidence. [6][7]8

Diabetes mellitus independently raises the risk of CKD by approximately 30 %; therefore, assessment for diabetic kidney disease should be performed before attributing CKD to dioxin exposure. (Evidence from Praxis Medical Insights; moderate observational strength.) 9
In patients with diabetes, the presence of hypertension, rapidly progressive renal decline, active urinary sediment, or lack of diabetic retinopathy (in type 1 diabetes) suggests non‑diabetic causes and warrants referral to nephrology. (Supported by Diabetes Care clinical guidance.) [10][8]11

Individuals with confirmed elevated serum dioxin concentrations should undergo annual kidney monitoring, including measurement of UACR and eGFR, to detect early CKD progression. (Evidence from Diabetes Care; observational cohort.) 8

In the veteran cohort, CKD prevalence is more strongly linked to traditional risk factors—such as diabetes, hypertension, and aging—than to Agent‑Orange exposure, as demonstrated by epidemiological analyses published in the Annals of Internal Medicine. (Observational evidence.) [6][7]